Drug Type Small molecule drug |
Synonyms Clentiazem, Clentiazem maleate (JAN/USAN), Logna + [2] |
Target |
Action blockers |
Mechanism Cav2.2 blockers(Voltage-gated N-type calcium channel alpha-1B subunit blockers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC26H29ClN2O8S |
InChIKeyFTUXVMVEKYLKGE-WECFPGDBSA-N |
CAS Registry96128-92-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D03536 | Clentiazem maleate | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Angina Pectoris | NDA/BLA | Japan | - | |
Angina Pectoris | NDA/BLA | - | - | |
Hypertension | NDA/BLA | Japan | - | |
Hypertension | NDA/BLA | - | - | |
Tachycardia, Supraventricular | Clinical | Japan | - | |
Atherosclerosis | Preclinical | United States | - | - |
Atherosclerosis | Preclinical | Japan | - | |
Atherosclerosis | Preclinical | Canada | - | - |
Atherosclerosis | Preclinical | - | - | |
Reperfusion Injury | Preclinical | Japan | - |